Galapagos NV (NASDAQ:GLPG) Shares Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. raised its position in Galapagos NV (NASDAQ:GLPG) by 63.2% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,899 shares of the biotechnology company’s stock after buying an additional 1,510 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Galapagos were worth $112,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Headlands Technologies LLC boosted its stake in Galapagos by 949.3% during the first quarter. Headlands Technologies LLC now owns 787 shares of the biotechnology company’s stock worth $25,000 after buying an additional 712 shares during the period. GAMMA Investing LLC increased its holdings in Galapagos by 140.7% during the 3rd quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 736 shares during the period. Signaturefd LLC raised its holdings in Galapagos by 48.1% in the second quarter. Signaturefd LLC now owns 3,872 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 1,258 shares in the last quarter. Rhumbline Advisers increased its position in shares of Galapagos by 21.6% in the 2nd quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock valued at $113,000 after purchasing an additional 814 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Galapagos by 783.6% in the 1st quarter. BNP Paribas Financial Markets now owns 5,328 shares of the biotechnology company’s stock valued at $172,000 after purchasing an additional 4,725 shares in the last quarter. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Galapagos Stock Down 7.5 %

Shares of NASDAQ:GLPG opened at $26.44 on Friday. The company has a 50 day moving average of $29.19 and a two-hundred day moving average of $27.76. Galapagos NV has a 52-week low of $24.16 and a 52-week high of $42.46.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on GLPG. Leerink Partners began coverage on Galapagos in a research note on Monday, September 9th. They set a “market perform” rating and a $24.00 target price for the company. Raymond James downgraded Galapagos from an “outperform” rating to a “market perform” rating in a report on Friday, August 2nd. Finally, Leerink Partnrs raised Galapagos to a “hold” rating in a report on Monday, September 9th. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $31.00.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.